I am very pleased to welcome you to Pantomics, Inc., a company engaging in tissue array production and related services.​

​

To achieve high quality and homogeneity in tissue array products, we started our company with a dedicated tissue acquisition and processing system.  We have now built up a large volume of optimally processed tissues with comprehensive accompanying data including age, sex, diagnosis and appropriate grading/staging.  This rich repository has allowed us to make tissue arrays covering a wide range of normal, reactive, pre-malignant and malignant conditions.  I would like to invite you to experience our high quality products.

​

For more than 20 years, I have been working in the field of clinical, academic and biotech pathology, being heavily involved in the use of human tissues and their derivatives.  My group started to adopt tissue array technology soon after it was introduced in the late 90’s.  Tissue array technology greatly accelerated our gene expression profiling projects employing immunohistochemistry (IHC) and in situ hybridization (ISH).  With this technology, we were able to organize relevant and subtle histological changes into “pathology models’ that greatly helped us to eliminate targets unrelated to disease during the drug discovery process in my former biotech company. Despite their usefulness, we noticed that IHC and ISH analyses on tissue arrays often required extra efforts in protocol optimization.  This was due to construction of arrays from heterogeneous tissue blocks of different quality caused by variation in storage age and fixation/processing history.  Our accumulated experience in the use of tissue arrays has become the foundation for setting up Pantomics, Inc., and for designing and providing our array products and array-based services.

​

Our website provides a wealth of information about our products and services.  I hope that you enjoy your time spent here.  We look forward to establishing a long and fruitful relationship with you, and thank you for your interest in our company.

​

Sincerely,

​

​

Langxing Pan, M.D., Ph.D.

​